Investor RelationsMike Brophy, CFO, Natera, Inc., 650-249-9090, Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com, Accounts receivable, net of allowance of $3,080 in 2020 and $2,919 in 2019, Prepaid expenses and other current assets, net, Operating lease liabilities, long-term portion, Total liabilities and stockholders' equity. ", Second Quarter Ended June 30, 2020 Financial Results. Natera anticipates 2020 total revenue of $345 million to $365 million; 2020 cost of revenues to be approximately 51% to 55% of revenues; selling, general and administrative costs to be approximately $260 million to $280 million; research and development costs to be $85 million to $95 million, and net cash burn to be $125 million to $155 million**. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Natera Reports Third Quarter 2019 Financial Results. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. I found out yesterday after a week of waiting, that I had to do a redraw! All Rights Reserved. Natera, Inc. Q3 2019 Earnings Conference Call. Most results will be returned to your doctor within 5-7 calendar days, but it can take about two weeks from the date of your blood draw before you can see them online via the Patient Portal. "We posted another very strong volume and revenue result despite the COVID-19 impact, and we achieved major milestones across the oncology and transplant businesses. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Natera Announces Third Quarter 2020 Earnings Conference Call, Natera, Inc. Q3 2020 Earnings Conference Call, Natera Announces Second Quarter 2020 Earnings Conference Call, Natera, Inc. Q2 2020 Earnings Conference Call, Natera Reports First Quarter 2020 Financial Results, Natera, Inc. Q1 2020 Earnings Conference Call, Natera Reports Fourth Quarter and Year 2019 Financial Results, Natera, Inc. Q4 2019 Earnings Conference Call, Natera Reports Third Quarter 2019 Financial Results, Natera, Inc. Q3 2019 Earnings Conference Call, Natera Reports Second Quarter 2019 Financial Results, Natera, Inc. Q2 2019 Earnings Conference Call, Natera Reports First Quarter 2019 Financial Results, Natera, Inc. Q1 2019 Earnings Conference Call, Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results, Natera, Inc. Q4 2018 Earnings Conference Call, Natera Reports Third Quarter 2018 Financial Results, Natera, Inc. Q3 2018 Earnings Conference Call, Natera Reports Second Quarter 2018 Financial Results, Natera, Inc. Q2 2018 Earnings Conference Call, Natera Reports First Quarter 2018 Financial Results, Natera, Inc. Q1 2018 Earnings Conference Call, Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results, Natera, Inc. Q4 2017 Earnings Conference Call, Natera Reports Third Quarter 2017 Financial Results, Natera, Inc. Q3 2017 Earnings Conference Call, Natera Reports Second Quarter 2017 Financial Results, Natera, Inc. Q2 2017 Earnings Conference Call, Natera Reports First Quarter 2017 Financial Results, Natera, Inc. Q1 2017 Earnings Conference Call, Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results, Natera Inc Q4 2016 Earnings Conference Call, Natera Reports Third Quarter 2016 Financial Results, Natera Inc Q3 2016 Earnings Conference Call, Natera Reports Second Quarter 2016 Financial Results, Natera Inc Q2 2016 Earnings Conference Call, Natera Reports First Quarter 2016 Financial Results, Natera Inc Q1 2016 Earnings Conference Call. In the three months ended June 30, 2020, Natera recognized revenue on approximately 220,000 tests for which results were reported to customers in the period (tests reported), including approximately 208,400 tests reported in its laboratory, compared to approximately 187,600 tests reported, including approximately 174,800 tests reported in its laboratory, in the second quarter of 2019. Natera Reports Second Quarter 2020 Financial Results, The condensed, consolidated balance sheet at, http://www.prnewswire.com/news-releases/natera-reports-second-quarter-2020-financial-results-301106974.html. Q4 Earnings. The company was able to achieve higher margins in the second quarter of 2020 primarily because of improved cost of goods sold per test and increased revenues. Natera, Inc. Q1 2020 Earnings Conference Call. You will receive your results from your doctor’s office. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC's website at www.sec.gov. Loss from operations for the second quarter of 2020 was $51.6 million compared to $28.6 million for the same period of the prior year. What do the numbers on the Statement of Results mean?Your HPAT Statement of Results will display two measures of your performance: HPAT score and HPAT percentile. Q3 Earnings. © Natera 2020. Your overall HPAT score is a weighted sum of your three section scores. They said it'd be about a week so I'm hoping to get them soon! A candidate must get 270 electoral votes to win the White House. Natera is a global leader in cell-free DNA testing. Gross margin is calculated as gross profit divided by GAAP total revenues. How Long Does It Normally Take To Get U.S. Election Results? How long did it take you to get your results? All Rights Reserved. The convertible senior notes were issued in April 2020 for net proceeds of $278.9 million, of which a portion was used to repay the $79.2 million obligations under the company's 2017 term loan with OrbiMed Advisors. A webcast replay will be available at investor.natera.com. Q2 Earnings. Natera Reports First Quarter 2020 Financial Results. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. The following slide deck was published by Natera, Inc. in conjunction with their 2020 Q3 earnings call. Net loss for the second quarter of 2020 was $59.6 million, or ($0.75) per diluted share, compared to net loss of $32.4 million, or ($0.48) per diluted share, for the same period in 2019. As of June 30, 2020, there were approximately 79,717,000 shares of common stock issued and outstanding. ** Cash burn is calculated as the sum of GAAP net cash used by operating activities (estimated for 2020 to be between $117 million and $147 million) and GAAP net purchases of property and equipment (estimated for 2020 to be approximately $8 million). Additional risks and uncertainties that could affect our financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time.